Woessner R - Search Results

1

Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.

Bruin G, Hockey HP, La Stella P, Sigurgeirsson B, Fu R, Patekar M, Charef P, Woessner R, Boutouyrie-Dumont B. Bruin G, et al. Among authors: woessner r. Br J Clin Pharmacol. 2020 Feb;86(2):338-351. doi: 10.1111/bcp.14155. Epub 2020 Jan 7. Br J Clin Pharmacol. 2020. PMID: 31658377 Free PMC article.

2

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.

Bruin G, Hasselberg A, Koroleva I, Milojevic J, Calonder C, Soon R, Woessner R, Pariser DM, Boutouyrie-Dumont B. Bruin G, et al. Among authors: woessner r. Clin Pharmacol Ther. 2019 Dec;106(6):1380-1388. doi: 10.1002/cpt.1558. Epub 2019 Aug 3. Clin Pharmacol Ther. 2019. PMID: 31228872 Free PMC article.

3

Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion.

Dragatin C, Polus F, Bodenlenz M, Calonder C, Aigner B, Tiffner KI, Mader JK, Ratzer M, Woessner R, Pieber TR, Cheng Y, Loesche C, Sinner F, Bruin G. Dragatin C, et al. Among authors: woessner r. Exp Dermatol. 2016 Feb;25(2):157-9. doi: 10.1111/exd.12863. Epub 2015 Nov 23. Exp Dermatol. 2016. PMID: 26439798 No abstract available.

4

Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

De Buck S, Hueber W, Vitaliti A, Straube F, Emotte C, Bruin G, Woessner R. De Buck S, et al. Among authors: woessner r. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. doi: 10.1002/psp4.12037. Epub 2015 Nov 9. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26904383 Free PMC article.

5

Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.

Chen J, Gu J, Shah B, Stringer R, Reis da Silva Torrao L, Hackling M, Nidamarthy PK, Prince WT, Woessner R. Chen J, et al. Among authors: woessner r. J Clin Pharmacol. 2022 Apr;62(4):520-531. doi: 10.1002/jcph.1996. Epub 2022 Feb 24. J Clin Pharmacol. 2022. PMID: 34738233

6

Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.

Chen J, Stringer R, Shah B, Gu J, Zhang Y, Hackling M, Prince W, Woessner R. Chen J, et al. Among authors: woessner r. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1253-1263. doi: 10.1002/cpdd.1140. Epub 2022 Aug 12. Clin Pharmacol Drug Dev. 2022. PMID: 35962468

7

Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.

Poller B, Woessner R, Barve A, Tillmann HC, Vemula J, Nica A, Elbast W, Schiller H, End P, Camenisch G, Weiss M. Poller B, et al. Among authors: woessner r. Pulm Pharmacol Ther. 2019 Aug;57:101809. doi: 10.1016/j.pupt.2019.101809. Epub 2019 Jun 10. Pulm Pharmacol Ther. 2019. PMID: 31195091

8

Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations.

Matsushima S, Matthews I, Woessner R, Pinault G, Hara H, Wilkins J, Sekiguchi K. Matsushima S, et al. Among authors: woessner r. Int J Clin Pharmacol Ther. 2012 Aug;50(8):545-56. doi: 10.5414/CP201719. Int J Clin Pharmacol Ther. 2012. PMID: 22735463

9

Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.

Vaidya SS, Khindri S, Calder N, Machineni S, Hara H, Majumdar T, Febbraro S, Fuhr R, Woessner R. Vaidya SS, et al. Among authors: woessner r. Pulm Pharmacol Ther. 2016 Apr;37:30-6. doi: 10.1016/j.pupt.2016.01.004. Epub 2016 Feb 1. Pulm Pharmacol Ther. 2016. PMID: 26845343 Clinical Trial.

10

Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.

Hosoe M, Woessner R, Matsushima S, Lawrence D, Kramer B. Hosoe M, et al. Among authors: woessner r. Clin Drug Investig. 2011;31(4):247-55. doi: 10.2165/11586520-000000000-00000. Clin Drug Investig. 2011. PMID: 21184620 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters